ScholarLens Back to search
1987•PubMedRequires access

Comparative measurement of ovarian carcinoma antigen and carcinoembryonic antigen in the serum of ovarian cancer.

Yuan Cc, H T Ng, Tsai Lc, Jeng Fs, Yeh Sh, Y-C Tsai

Open publisher page 1 citations

Abstract

Serum ovarian carcinoma antigen (CA 125) and carcinoembryonic antigen (CEA) were measured in 36 patients with ovarian cancer, to compare their effects and assess clinical applications. The positive rate of CA 125 was significantly higher than CEA, ie, 72.2% v.s. 33.3% in all types of ovarian cancer, 81.3% v.s. 31.3% in the 32 epithelial cancers, and even more of 100% v.s. 25% in the 16 serous cystadenocarcinoma. The positive rate of CA 125 was also higher than CEA in borderline malignancy and stage-I cancers, a possible indication of its greater usefulness in early diagnosis. CA 125 was also a better marker in monitoring of epithelial ovarian cancer than CEA. Combining use of these two markers achieved an even higher positive rate. Therefore it seems useful to utilize them concomitantly in the diagnosis of ovarian cancers.

About this research paper

What this paper is about

Serum ovarian carcinoma antigen (CA 125) and carcinoembryonic antigen (CEA) were measured in 36 patients with ovarian cancer, to compare their effects and assess clinical applications. The positive rate of CA 125 was significantly higher than CEA, ie, 72.2% v.s. 33.3% in all types of ovarian cancer, 81.3% v.s. 31.3% in the 32 epithelial cancers, and even more of 100% v.s. 25% in the 16 serous cystadenocarcinoma. The positive rate of CA 125 was also higher than CEA in borderline malignancy and stage-I cancers, a possible indication of its greater usefulness in early diagnosis. CA 125 was also a better marker in monitoring of epithelial ovarian cancer than CEA. Combining use of these two markers achieved an even higher positive rate. Therefore it seems useful to utilize them concomitantly in the diagnosis of ovarian cancers.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Serum ovarian carcinoma antigen (CA 125) and carcinoembryonic antigen (CEA) were measured in 36 patients with ovarian cancer, to compare their effects and assess clinical applications. The positive rate of CA 125 was significantly higher than CEA, ie, 72.2% v.s. 33.3% in all types of ovarian cancer, 81.3% v.s. 31.3% in the 32 epithelial cancers, and even more of 100% v.s. 25% in the 16 serous cystadenocarcinoma. The positive rate of CA 125 was also higher than CEA in borderline malignancy and stage-I cancers, a possible indication of its greater usefulness in early diagnosis. CA 125 was also a better marker in monitoring of epithelial ovarian cancer than CEA. Combining use of these two markers achieved an even higher positive rate. Therefore it seems useful to utilize them concomitantly in the diagnosis of ovarian cancers.

Key concepts: Carcinoembryonic antigen, Serous cystadenocarcinoma, Ovarian cancer, Cancer antigen, Medicine, Ovarian carcinoma, Cystadenocarcinoma, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Comparative measurement of ovarian carcinoma antigen and carcinoembryonic antigen in the serum of ovarian cancer. — Research Paper | ScholarLens